Nitrosamines and NDSRIs for risk assessment
Small-molecule nitrosamines and nitrosamine drug substance-related impurities (NDSRIs) as reference materials for confirmatory testing, CPCA categorization and acceptable intake (AI) justification under current FDA, EMA and ICH M7 expectations.
CPCA
potency categories
ppm
typical LOQ band
NDSRI
vs small nitrosamine
AI
limit derivation
2025+
submission horizon
NDSRI vs small nitrosamines
Small nitrosamines (e.g. NDMA, NDEA) are often evaluated against published AI limits derived from carcinogenic potency categorization (CPCA) and historical guidance for sartan and ranitidine investigations.
NDSRIs form in situ when an amine on the drug substance (or a structural alert in the synthesis route) reacts with nitrosating agents. Their limits depend on CPCA category, daily dose and duration; confirmatory methods use LC-MS/MS with isotope dilution.
CPCA potency categories and indicative AI bands
Acceptable intakes are expressed in ng/day and converted to ppm in drug product using maximum daily dose (MDD). Values below are illustrative of public FDA/EMA communication patterns — confirm against current agency tables for your substance.
| CPCA category | Potency signal | Indicative AI (ng/day) | Implementation notes |
|---|---|---|---|
| Category 1 | Highly potent structural features | ~18 | Tightest control; analytical challenge at low MDD |
| Category 2 | Elevated concern | ~100 | Common target for NDSRI method validation |
| Category 3 | Moderate | ~400 | May align with interim limits during mitigation |
| Category 4 | Lower predicted potency | ~1500 | Still requires documented risk assessment |
| Category 5 | Lowest CPCA band in framework | ~1500–higher interim | Agency interim limits may apply by class |
Source: www.fda.gov
Last reviewed: 2026-01-15
When to treat the analyte as NDSRI or small nitrosamine
| Observation | Interpretation | Standard type |
|---|---|---|
| Mass matches drug + NO moiety | Likely NDSRI of parent API | Custom or synthesized NDSRI reference; isotope dilution |
| Known small nitrosamine (e.g. NDMA) | Process or excipient route | Compendial or commercial small nitrosamine CRM |
| Multiple nitrosated structures | Route and packaging risk | Bracket with worst-case CPCA category |
| Below LOQ, alert present | Risk assessment only | Method qualification without release limit until confirmed |
Figures are indicative industry-typical values. Lot- and project-specific data appear on the quotation and certificate of analysis.
Indicative regulatory timeline
Milestones vary by region and product class. Dates are planning aids, not legal deadlines.
Phase 1 — Assessment
Manufacturing
Map nitrosating agents, amines, recycled solvents
Analytics
Screening LC-MS/MS methods; set provisional LOQs
Regulatory
Document risk assessment per ICH M7 / Q9
Phase 2 — Confirm & mitigate
Manufacturing
Adjust routes, antioxidants, packaging
Analytics
Validate confirmatory method; NDSRI standards
Regulatory
Submit protocol updates and stability commitments
Phase 3 — Ongoing
Manufacturing
Control strategy in CMC
Analytics
Routine monitoring at release and stability
Stability
Track nitrosamine formation on shelf
Regulatory
Annual report and variation as limits evolve
Reference standard analytical package
Identity
HRMS or LC-MS/MS
Exact mass and fragmentation
Purity
≥95% typical
Separate from response factor
Isotope dilution
Optional co-pack
Stable-isotope labeled analogue
Solution stability
Study on request
Acidic aqueous often used short term
Concentration
µg/mL to mg/mL
Matched to method LOQ
Figures are indicative industry-typical values. Lot- and project-specific data appear on the quotation and certificate of analysis.
Indicative confirmatory testing sequence
- 01
Extract drug product or substance per validated procedure (avoid artifact nitrosation).
- 02
Analyze by LC-MS/MS with multiple reaction monitoring.
- 03
Confirm peak with reference standard and isotope dilution recovery 80–120%.
- 04
Convert ng/day AI to ppm limit using MDD; compare to batch result.
- 05
Document root cause and CAPA in quality system if above interim limit.
Frequently asked questions
Yes. Small nitrosamines for cross-checking process routes are available; NDSRIs are project-specific structures tied to the parent API.
Related
Stable-Isotope Standards
Deuterated and 13C-labeled impurities, metabolites and APIs for isotope dilution quantitation — minimizing matrix suppression effects in bioanalysis and nitrosamine confirmatory methods.
View detailsCertified Reference Materials
Impurities and API-related CRMs with certified property values, measurement uncertainty and metrological traceability — produced or distributed under principles aligned with ISO 17034 for method validation and lab accreditation.
View detailsCustom Impurity Synthesis
When catalogue search does not return your peak, we design a synthesis or isolation route for deletion peptides, genotoxic alerts, nitrosamines, metabolites and chiral variants — with a documented package for qualification.
View detailsOncology Reference Standards
Impurities, degradants and reference standards for cytotoxic and targeted oncology APIs — supporting potency assays, related-substances control and nitrosamine risk assessment in high-potency handling environments.
View detailsReady to specify this for your program?
Share sequence, scale and documentation needs. We reply with indicative specs and a project-specific quotation.